![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
Preview |
PDF (Supplemental Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
36MB |
| Item Type: | Article |
|---|---|
| Title: | Base editing repairs an SGCA mutation in human primary muscle stem cells |
| Creators Name: | Escobar, H., Krause, A., Keiper, S., Kieshauer, J., Müthel, S., García de Paredes, M., Metzler, E., Kühn, R., Heyd, F. and Spuler, S. |
| Abstract: | Skeletal muscle can regenerate from muscle stem cells and their myogenic precursor cell progeny, myoblasts. However, precise gene editing in human muscle stem cells for autologous cell replacement therapies of untreatable genetic muscle diseases has not yet been reported. Loss-of-function mutations in SGCA, encoding α-sarcoglycan, cause limb-girdle muscular dystrophy 2D/R3, an early onset, severe and rapidly progressive form of muscular dystrophy affecting equally girls and boys. Patients suffer from muscle degeneration and atrophy affecting the limbs, respiratory muscles, and the heart. We isolated human muscle stem cells from two donors with the common SGCA c.157G>A mutation affecting the last coding nucleotide of exon 2. We found that c.157G>A is an exonic splicing mutation that induces skipping of two co-regulated exons. Using adenine base editing, we corrected the mutation in the cells from both donors with >90% efficiency, thereby rescuing the splicing defect and α-sarcoglycan expression. Base edited patient cells regenerated muscle and contributed to the Pax7 positive satellite cell compartment in vivo in mouse xenografts. We hereby provide the first evidence that autologous gene repaired human muscle stem cells can be harnessed for cell replacement therapies of muscular dystrophies. ONE SENTENCE SUMMARY: Patient primary muscle stems cells gene repaired with >90% efficiency by base editing maintain their regenerative properties for autologous cell replacement therapies of muscular dystrophy. |
| Keywords: | CRISPR-Cas Systems, Cell- and Tissue-Based Therapy, Gene Editing, Heterografts, Limb-Girdle Muscular Dystrophies, Muscle Development, Mutation, Myoblasts, Sarcoglycans, Skeletal Muscle, Animals, Mice |
| Source: | JCI Insight |
| ISSN: | 2379-3708 |
| Publisher: | American Society for Clinical Investigation |
| Volume: | 6 |
| Number: | 10 |
| Page Range: | e145994 |
| Date: | 24 May 2021 |
| Official Publication: | https://doi.org/10.1172/jci.insight.145994 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
